Stuart Rich - 12 Oct 2021 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
Chief Medical Officer, Director, 10%+ Owner
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
12 Oct 2021
Net transactions value
$0
Form type
4
Filing time
06 Dec 2021, 16:08:55 UTC
Previous filing
15 Jun 2021
Next filing
10 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TENX Common Stock Gift $0 -1,909,585 -45% $0.000000 2,333,932 12 Oct 2021 Direct
transaction TENX Common stock Gift $0 +1,909,585 $0.000000 1,909,585 12 Oct 2021 By Spouse
transaction TENX Common stock Gift $0 -1,909,585 -100% $0.000000* 0 29 Nov 2021 By Spouse F1
transaction TENX Common Stock Gift $0 +1,909,585 $0.000000 1,909,585 29 Nov 2021 By Andrea Rich 2021 Irrevocable Trust F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TENX Stock Option (right to buy) 250,000 12 Oct 2021 Common Stock 250,000 $1.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Stuart Rich is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents a gift of Issuer's common stock to the Andrea Rich 2021 Irrevocable Trust, a Spousal Lifetime Access Trust (the "Trust"), for the benefit of the Reporting Person and the Reporting Person's children.
F2 The Reporting Person is co-trustee of the Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3 The option becomes exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA.

Remarks:

Exhibit 24 - Power of Attorney